Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YK0901 in KRAS G12V+ Advanced Solid Tumors
NCT05933668Phase 1Not yet recruiting
- Sponsor
- Peking University
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YK0901 in solid tumor (advanced stage), sponsored by Peking University. Primary endpoints: Dose-limiting toxicity at 2 years and Treatment related Adverse Events at 2 years. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
YK0901
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05933668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933668.